More than a year after it issued an initial warning about the use of the multiple sclerosis (MS) drug Gilenya (fingolimod) after it was associated with an increased risk of adverse cardiovascular ...

The US Food and Drug Administration (FDA) has placed new contraindications on Novartis' Multiple Sclerosis drug Gilenya (fingolimod) after investigating the cases of several patients who died soon ...

The agency previously approved Gilenya, a disease-modifying therapy, for adults with relapsing forms of multiple sclerosis. The treatment may now also be used for children ages 10 and up with the same ...

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The case further ...